The NIBSC will be working to support the design and establishment of a sustainable European vaccine infrastructure as part of a new EC-funded project.
TRANSVAC-DS, which officially started on 01 June 2020, is being coordinated by the European Vaccine Initiative and involves a consortium of 25 partner organisations from across eleven countries.
It follows on from the TRANSVAC1 and TRANSVAC2 projects (www.transvac.org), which the NIBSC have also contributed to. These infrastructure projects laid the groundwork to facilitate the translation of biomedical research into effective vaccines through the provision of state-of-the-art resources and expertise.
It is hoped that TRANSVAC-DS will build on these successes and that by the end of the two-year project, a sustainable European vaccine infrastructure will be ready to move rapidly into the implementation and operation phases.
The NIBSC is involved in several work packages including a ‘gaps and needs’ analysis of the research infrastructure landscape and the development of a stakeholder engagement strategy. The institute will also be assisting with work focused on the identification of any ethical issues that could arise from a future permanent vaccine R&D infrastructure and devising strategies for handling them.
The ultimate goal is the establishment of a truly sustainable European vaccine infrastructure that will accelerate the development of safe, effective and affordable vaccines for global public health.
Further information about TRANSVAC-DS is available here.